Andreas Pettersson1, Rosina T Lis, Allison Meisner, Richard Flavin, Edward C Stack, Michelangelo Fiorentino, Stephen Finn, Rebecca E Graff, Kathryn L Penney, Jennifer R Rider, Elizabeth J Nuttall, Neil E Martin, Howard D Sesso, Michael Pollak, Meir J Stampfer, Philip W Kantoff, Edward L Giovannucci, Massimo Loda, Lorelei A Mucci. 1. Affiliations of authors: Department of Epidemiology (AP, AM, MF, REG, KLP, JRR, EJN, MJS, ELG, LAM) and Department of Nutrition (MJS, ELG), Harvard School of Public Health, Boston, MA; Channing Division of Network Medicine (AP, KLP, JRR, MJS, ELG, LAM) and Division of Preventive Medicine (HDS) , Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Pathology, Brigham and Women's Hospital, Boston, MA (RTL, ECS, ML); Center for Molecular Oncologic Pathology (RTL, RF, ECS, MF, SF, NEM, ML), Department of Radiation Oncology (NEM), and Lank Center for Genitourinary Oncology (PWK), Dana-Farber Cancer Institute, Boston, MA; University of Dublin, Trinity College, Dublin, Ireland (RF, SF); Pathology Unit, Addarii Institute, S. Orsola-Malpighi Hospital, Bologna, Italy (MF); Department of Medicine, McGill University, Montreal, QC, Canada (MP).
Abstract
BACKGROUND: TMPRSS2:ERG is a hormonally regulated gene fusion present in about half of prostate tumors. We investigated whether obesity, which deregulates several hormonal pathways, interacts with TMPRSS2:ERG to impact prostate cancer outcomes. METHODS: The study included 1243 participants in the prospective Physicians' Health Study and Health Professionals Follow-Up Study diagnosed with prostate cancer between 1982 and 2005. ERG overexpression (a TMPRSS2:ERG marker) was assessed by immunohistochemistry of tumor tissue from radical prostatectomy or transurethral resection of the prostate. Body mass index (BMI) and waist circumference, measured on average 1.3 years and 5.3 years before diagnosis, respectively, were available from questionnaires. Data on BMI at baseline was also available. We used Cox regression to calculate hazard ratios and 95% confidence intervals (CIs). All statistical tests were two-sided. RESULTS: During a mean follow-up of 12.8 years, 119 men developed lethal disease (distant metastases or prostate cancer death). Among men with ERG-positive tumors, the multivariable hazard ratio for lethal prostate cancer was 1.48 (95% CI = 0.98 to 2.23) per 5-unit increase in BMI before diagnosis, 2.51 (95% CI = 1.26 to 4.99) per 8-inch increase in waist circumference before diagnosis, and 2.22 (95% CI = 1.35 to 3.63) per 5-unit increase in BMI at baseline. The corresponding hazard ratios among men with ERG-negative tumors were 1.10 (95% CI = 0.76 to1.59; P interaction = .24), 1.14 (95% CI = 0.62 to 2.10; P interaction = .09), and 0.78 (95% CI = 0.52 to 1.19; P interaction = .001). CONCLUSIONS: These results suggest that obesity is linked with poorer prostate cancer prognosis primarily in men with tumors harboring the gene fusion TMPRSS2:ERG.
BACKGROUND:TMPRSS2:ERG is a hormonally regulated gene fusion present in about half of prostate tumors. We investigated whether obesity, which deregulates several hormonal pathways, interacts with TMPRSS2:ERG to impact prostate cancer outcomes. METHODS: The study included 1243 participants in the prospective Physicians' Health Study and Health Professionals Follow-Up Study diagnosed with prostate cancer between 1982 and 2005. ERG overexpression (a TMPRSS2:ERG marker) was assessed by immunohistochemistry of tumor tissue from radical prostatectomy or transurethral resection of the prostate. Body mass index (BMI) and waist circumference, measured on average 1.3 years and 5.3 years before diagnosis, respectively, were available from questionnaires. Data on BMI at baseline was also available. We used Cox regression to calculate hazard ratios and 95% confidence intervals (CIs). All statistical tests were two-sided. RESULTS: During a mean follow-up of 12.8 years, 119 men developed lethal disease (distant metastases or prostate cancer death). Among men with ERG-positive tumors, the multivariable hazard ratio for lethal prostate cancer was 1.48 (95% CI = 0.98 to 2.23) per 5-unit increase in BMI before diagnosis, 2.51 (95% CI = 1.26 to 4.99) per 8-inch increase in waist circumference before diagnosis, and 2.22 (95% CI = 1.35 to 3.63) per 5-unit increase in BMI at baseline. The corresponding hazard ratios among men with ERG-negative tumors were 1.10 (95% CI = 0.76 to1.59; P interaction = .24), 1.14 (95% CI = 0.62 to 2.10; P interaction = .09), and 0.78 (95% CI = 0.52 to 1.19; P interaction = .001). CONCLUSIONS: These results suggest that obesity is linked with poorer prostate cancer prognosis primarily in men with tumors harboring the gene fusion TMPRSS2:ERG.
Authors: Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan Journal: Science Date: 2005-10-28 Impact factor: 47.728
Authors: Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-26 Impact factor: 4.254
Authors: Christopher J Keto; William J Aronson; Martha K Terris; Joseph C Presti; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: BJU Int Date: 2011-11-17 Impact factor: 5.588
Authors: F Demichelis; K Fall; S Perner; O Andrén; F Schmidt; S R Setlur; Y Hoshida; J-M Mosquera; Y Pawitan; C Lee; H-O Adami; L A Mucci; P W Kantoff; S-O Andersson; A M Chinnaiyan; J-E Johansson; M A Rubin Journal: Oncogene Date: 2007-01-22 Impact factor: 9.867
Authors: Jing Ma; Haojie Li; Ed Giovannucci; Lorelei Mucci; Weiliang Qiu; Paul L Nguyen; J Michael Gaziano; Michael Pollak; Meir J Stampfer Journal: Lancet Oncol Date: 2008-10-03 Impact factor: 41.316
Authors: Sunita R Setlur; Kirsten D Mertz; Yujin Hoshida; Francesca Demichelis; Mathieu Lupien; Sven Perner; Andrea Sboner; Yudi Pawitan; Ove Andrén; Laura A Johnson; Jeff Tang; Hans-Olov Adami; Stefano Calza; Arul M Chinnaiyan; Daniel Rhodes; Scott Tomlins; Katja Fall; Lorelei A Mucci; Philip W Kantoff; Meir J Stampfer; Swen-Olof Andersson; Eberhard Varenhorst; Jan-Erik Johansson; Myles Brown; Todd R Golub; Mark A Rubin Journal: J Natl Cancer Inst Date: 2008-05-27 Impact factor: 13.506
Authors: Ericka M Ebot; Travis Gerke; David P Labbé; Jennifer A Sinnott; Giorgia Zadra; Jennifer R Rider; Svitlana Tyekucheva; Kathryn M Wilson; Rachel S Kelly; Irene M Shui; Massimo Loda; Philip W Kantoff; Stephen Finn; Matthew G Vander Heiden; Myles Brown; Edward L Giovannucci; Lorelei A Mucci Journal: Cancer Date: 2017-07-12 Impact factor: 6.860
Authors: Isabel R Schlaepfer; Leah Rider; Lindsey Ulkus Rodrigues; Miguel A Gijón; Colton T Pac; Lina Romero; Adela Cimic; S Joseph Sirintrapun; L Michael Glodé; Robert H Eckel; Scott D Cramer Journal: Mol Cancer Ther Date: 2014-08-13 Impact factor: 6.261
Authors: Piotr Zareba; Richard Flavin; Masis Isikbay; Jennifer R Rider; Travis A Gerke; Stephen Finn; Andreas Pettersson; Francesca Giunchi; Robert H Unger; Alex M Tinianow; Swen-Olof Andersson; Ove Andrén; Katja Fall; Michelangelo Fiorentino; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-01-06 Impact factor: 4.254
Authors: Alba Torres; Mohammed Alshalalfa; Scott A Tomlins; Nicholas Erho; Ewan A Gibb; Jijumon Chelliserry; Lony Lim; Lucia L C Lam; Sheila F Faraj; Stephania M Bezerra; Elai Davicioni; Kasra Yousefi; Ashley E Ross; George J Netto; Edward M Schaeffer; Tamara L Lotan Journal: J Mol Diagn Date: 2017-03-21 Impact factor: 5.568
Authors: Jennifer Cullen; Denise Young; Yongmei Chen; Michael Degon; James Farrell; Jason Sedarsky; Wagner Baptiste; Philip Rosen; Vladimir Tolstikov; Michael Kiebish; Jacob Kagan; Sudhir Srivastava; Huai-Ching Kuo; Joel T Moncur; Inger L Rosner; Niven Narain; Viatcheslav Akmaev; Gyorgy Petrovics; Albert Dobi; David G McLeod; Shiv Srivastava; Isabell A Sesterhenn Journal: Eur Urol Focus Date: 2017-03-11
Authors: Lieke Egbers; Manuel Luedeke; Antje Rinckleb; Suzanne Kolb; Jonathan L Wright; Christiane Maier; Marian L Neuhouser; Janet L Stanford Journal: Am J Epidemiol Date: 2015-04-07 Impact factor: 4.897
Authors: Saud Khan; Joshua Caldwell; Travis A Gerke; Sarah C Markt; Kathryn M Wilson; Amparo G Gonzalez-Feliciano; Samuel Peisch; Claire H Pernar; Rebecca E Graff; Edward L Giovannucci; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-04-10 Impact factor: 4.254
Authors: Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Rebecca E Graff; Carlos L Morais; Jessica L Hicks; Kathryn M Wilson; Jennifer R Rider; Howard D Sesso; Michelangelo Fiorentino; Richard Flavin; Stephen Finn; Edward L Giovannucci; Massimo Loda; Meir J Stampfer; Angelo M De Marzo; Lorelei A Mucci; Tamara L Lotan Journal: J Natl Cancer Inst Date: 2015-11-27 Impact factor: 13.506